Important Drug Interactions in Hematopoietic Stem Cell Transplantation: What Every Physician Should Know
Brett Glotzbecker(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Bonnie Campbell(Dana-Farber Cancer Institute), Christine Duncan(Dana-Farber Cancer Institute)
Cited by 96
Related Papers
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595
Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
|New England Journal of Medicine|2017|592
Hyponatremia among Runners in the Boston Marathon
|New England Journal of Medicine|2005|553
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468